To Main Menu ► 

January 2017 Newsletter

//January 2017 Newsletter

Tresiba gains FDA approval for use in children and adolescents

By | January 18th, 2017|Diabetes Bites, January 2017 Newsletter|

Children and adolescents age 1 and up now have another option in basal insulin. On December 19, 2016, Novo Nordisk announced that the FDA approved an expanded indication for Tresiba (insulin degludec injection 100 U/mL, 200 U/mL).

New Hope: Glucagon for the dual hormone artificial pancreas

By | January 18th, 2017|Diabetes Bites, January 2017 Newsletter|

We are all so eager for a commercially available closed-loop "bionic pancreas" system to hit the market. But glucagon isn't stable for any great length of time after it is reconstituted, so researchers are working on developing a more stable version of it. Read on to learn more about progress on that front!